Bold Prediction: Why CureVac is the Next Explosive Stock After Novavax

In April, I evaluated Novavax (NVAX) as a wise investment choice. At that time, Novavax's stock price was around $4, and now, within just a few months, it has soared to $20, a more than 500% increase. If you had invested $10,000 back then, it would have grown to $50,000 now. However, my post did not receive the recognition it deserved, and many people dismissed the idea, claiming that investing in Novavax was a mistake.

The reality has proven otherwise. For those who entered at $9 to $20, the growth rate is relatively lower but still profitable. Mathematically, it is all about timing your entry to maximize returns. Now, with Novavax's stock at $20, I boldly predict that it could continue to rise to $100 or even $200. If you entered at $4 and the stock reaches $100, your return would be 2500%.

Taking this opportunity, I would like to make another bold prediction: the next growth stock will be CureVac (CVAC). Here are my reasons:

Diversified Collaboration and R&D
CureVac is a diversified biopharmaceutical company collaborating with GlaxoSmithKline (GSK) to develop multiple vaccines, including COVID-19 vaccines and H5N1 avian flu vaccines. CureVac's second-generation COVID-19 vaccine has already completed Phase 2 trials with excellent results. Additionally, the H5N1 avian flu vaccine began its Phase 1/2 trials in April 2024​ (CureVac)

Market Prospects
The threats of COVID-19 and H5N1 avian flu still exist, especially with avian flu being highly transmissible and lethal. The potential market demand for these vaccines is enormous. CureVac's vaccine projects are expected to see market breakthroughs from Q4 2024 to 2025.

Undervalued Stock Price
Currently, CureVac's stock price is around $4 to $5, while it once peaked at $150. I believe CureVac's stock is severely undervalued, and the market has not fully recognized its potential and future market demand.

Investment Opportunity
For investors, now is an excellent time to enter CureVac. Assuming an entry at $4 and a future stock price of $100, your return would be 2500%. Even entering at the current higher prices still offers significant profit potential.

In conclusion, I believe CureVac will be a highly promising growth stock in the coming years. Let's watch and see if CureVac can achieve tremendous growth like Novavax.